Jun 2016;29(3):338-344
The contrast with placebo is even more pronounced in a post-hoc analysis at 24 weeks
3 g) and moderate interstitial inflammation with moderate thickening of the alveolar septa (Fig
"Regulatory surveillance will continue to be intensified in the coming weeks and non-compliance will be dealt strictly with actions, including cancellation of licenses, penalties, and prosecution under applicable laws. This comes in the backdrop of several domestic pharmaceutical companies, including Sun Pharma, Dr Reddys, Alkem, Torrent, Cipla, Zydus Lifesciences and Glenmark, launching generic versions of GLP-1 drug semaglutide following its patent expiry in India this month
Follow us INS to get seasonal discount information
113 (4): 44752 Rankin SJ, Walman BE, Buckley AR, et al